Bristol-Myers Squibb’s Five-Year Immuno-Oncology Legacy in China: Delivering Long-Term Survival and Expanding Access
HKDengyuemed stated, “In cancer care, achieving five-year survival is a critical milestone, often synonymous with long-term remission.” Marking the fifth anniversary of its “China 2030 Strategy,” Bristol-Myers Squibb (BMS) reflects on a period of significant…